Parveen Shiraz, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shiraz’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A67098 · Current
Licensed to practise in California · since 1998 · expires 2026-12-31 · University of Madras, Kilpauk Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,276
Medicare paid this office $16,276 for 43 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $7,558 | $106 |
| Long return visit (40+ min) | 16 | $4,705 | $118 |
| Long return visit (40+ min) | 12 | $3,329 | $151 |
Who their Medicare patients are
43 Original Medicare patients in 2024. Average age 66 · Women 51% · Also on Medicaid 28% · Health risk score 3.58. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 60% · Diabetes 26% · Chronic kidney disease 26%.
The office billed $58,483, Medicare allowed $21,609 and paid $16,276; for 138 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 43 | 138 | 66 | 3.58 | $58,483 | $16,276 |
| 2023 | 68 | 311 | 66 | 3.05 | $145,753 | $35,745 |
| 2022 | 54 | 153 | 67 | 2.30 | $73,730 | $17,248 |
| 2021 | 59 | 263 | 68 | 3.01 | $125,470 | $29,464 |
| 2020 | 85 | 529 | 66 | 3.12 | $220,632 | $54,984 |
| 2019 | 86 | 445 | 67 | 2.86 | $263,646 | $41,341 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $20,038 | $109 |
| Long return visit (40+ min) | 32 | $9,332 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,028 | $156 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,285 | $99 |
2022: 2 services
| Long return visit (40+ min) | 35 | $10,214 | $119 |
| Extended patient service without direct patient contact, first hour | 11 | $2,025 | $101 |
2021: 3 services
| Long return visit (40+ min) | 37 | $12,913 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $11,549 | $92 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,201 | $92 |
2020: 4 services
| Long return visit (40+ min) | 57 | $24,622 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $19,735 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,155 | $186 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,200 | $100 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $17,481 | $92 |
| Return visit (30+ min) | 24 | $8,486 | $71 |
| Long return visit (40+ min) | 33 | $6,168 | $99 |
| New patient visit (60+ min) | 13 | $1,895 | $146 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,270 | $98 |
Medicaid work
$1,996 in 2024
Medicaid paid $1,996 for 15 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $1,996 |
| 2024 | 15 | 1 | 13 | $1,996 |
| 2023 | 21 | 1 | 13 | $1,195 |
| 2022 | 86 | 1 | 21 | $13,109 |
| 2021 | 145 | 1 | 21 | $17,042 |
| 2020 | 145 | 1 | 26 | $10,140 |
| 2019 | 61 | 2 | 13 | $3,892 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 21 | $1,195 |
2022
| Long return visit (40+ min) | 86 | $13,109 |
2021
| Long return visit (40+ min) | 145 | $17,042 |
2020
| Long return visit (40+ min) | 145 | $10,140 |
2019
| Return visit (30+ min) | 39 | $2,540 |
| Long return visit (40+ min) | 22 | $1,352 |
Drugs they prescribed that Part D paid
$1,142,241
Pharmacies billed $1,142,241 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
359 generic and fewer than 11 brand-name prescriptions · $1,142,241 in drug cost · 74 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rezurock | 39 | $715,238 | $18,339 |
| Jakafi | 24 | $218,991 | $9,125 |
| Sprycel | 15 | $149,126 | $9,942 |
| Atovaquone | 11 | $4,436 | $403 |
| Budesonide Dr | 13 | $2,381 | $183 |
See all 15 drugs
| Rezurock | 39 | $715,238 | $18,339 |
| Jakafi | 24 | $218,991 | $9,125 |
| Sprycel | 15 | $149,126 | $9,942 |
| Atovaquone | 11 | $4,436 | $403 |
| Budesonide Dr | 13 | $2,381 | $183 |
| Sirolimus | 14 | $1,856 | $133 |
| Acyclovir | 84 | $1,549 | $18 |
| Dexamethasone | 12 | $921 | $77 |
| Sulfamethoxazole-Trimethoprim | 59 | $472 | $8 |
| Tacrolimus | 11 | $467 | $42 |
| Potassium Chloride | 11 | $258 | $23 |
| Gabapentin | 17 | $194 | $11 |
| Pantoprazole | 11 | $179 | $16 |
| Prednisone | 11 | $115 | $10 |
| Amoxicillin | 13 | $49 | $4 |
Year by year
| 2024 | 451 | 31 | None | None | $1,142,241 |
| 2023 | 301 | 26 | None | 10% | $383,946 |
| 2022 | 372 | 30 | 0% (0) | 15% | $552,967 |
| 2021 | 306 | 22 | 0% (0) | 10% | $279,363 |
| 2020 | 286 | 33 | 0% (0) | 7% | $123,117 |
| 2019 | 294 | 68 | None | 21% | $580,840 |
| 2018 | 725 | 116 | 6% (46) | None | $2,697,856 |
| 2017 | 426 | 94 | 8% (35) | None | $1,211,399 |
| 2016 | 82 | 36 | None | 30% | $137,255 |
| 2015 | 161 | 27 | 8% (12) | 11% | $44,371 |
| 2014 | 181 | 27 | None | 27% | $170,173 |
| 2013 | 172 | 37 | 7% (12) | None | $112,826 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Jakafi | 13 | $123,334 | $9,487 |
| Posaconazole | 27 | $58,960 | $2,184 |
| Atovaquone | 20 | $10,796 | $540 |
| Sirolimus | 22 | $3,811 | $173 |
| Acyclovir | 49 | $1,823 | $37 |
| Sulfamethoxazole-Trimethoprim | 39 | $367 | $9 |
| Pantoprazole | 15 | $231 | $15 |
| Prednisone | 11 | $126 | $11 |
2022: 9 drugs
| Sprycel | 12 | $113,926 | $9,494 |
| Posaconazole | 22 | $46,257 | $2,103 |
| Atovaquone | 26 | $16,216 | $624 |
| Acyclovir | 60 | $2,171 | $36 |
| Dexamethasone | 28 | $828 | $30 |
| Tacrolimus | 18 | $563 | $31 |
| Sulfamethoxazole-Trimethoprim | 54 | $406 | $8 |
| Pantoprazole | 13 | $228 | $18 |
| Prednisone | 12 | $99 | $8 |
2021: 6 drugs
| Atovaquone | 22 | $11,560 | $525 |
| Acyclovir | 45 | $1,802 | $40 |
| Dexamethasone | 35 | $1,542 | $44 |
| Nystatin | 20 | $1,015 | $51 |
| Tacrolimus | 13 | $569 | $44 |
| Sulfamethoxazole-Trimethoprim | 41 | $451 | $11 |
2020: 9 drugs
| Acyclovir | 52 | $1,573 | $30 |
| Tacrolimus | 15 | $1,491 | $99 |
| Ondansetron | 17 | $335 | $20 |
| Famotidine | 15 | $184 | $12 |
| Lorazepam | 21 | $138 | $7 |
| Levofloxacin | 11 | $137 | $12 |
| Prednisone | 11 | $95 | $9 |
| Sulfamethoxazole-Trimethoprim | 11 | $92 | $8 |
| Pantoprazole | 12 | $69 | $6 |
2019: 7 drugs
| Imbruvica | 29 | $343,768 | $11,854 |
| Jakafi | 11 | $157,267 | $14,297 |
| Hydroxyurea | 32 | $1,835 | $57 |
| Anastrozole | 29 | $706 | $24 |
| Acyclovir | 29 | $684 | $24 |
| Omeprazole | 12 | $153 | $13 |
| Sulfamethoxazole-Trimethoprim | 13 | $81 | $6 |
2018: 16 drugs
| Imbruvica | 88 | $1,029,570 | $11,700 |
| Pomalyst | 36 | $617,999 | $17,167 |
| Revlimid | 23 | $383,000 | $16,652 |
| Jakafi | 22 | $289,419 | $13,155 |
| Venclexta | 25 | $225,700 | $9,028 |
| Hydroxyurea | 42 | $3,306 | $79 |
| Exemestane | 11 | $2,436 | $221 |
| Morphine Sulfate | 13 | $2,114 | $163 |
| Dexamethasone | 34 | $1,929 | $57 |
| Anastrozole | 41 | $1,060 | $26 |
| Anagrelide | 11 | $1,053 | $96 |
| Acyclovir | 46 | $985 | $21 |
| Allopurinol | 23 | $493 | $21 |
| Ondansetron | 31 | $396 | $13 |
| Prednisone | 18 | $316 | $18 |
| Hydrocodone-Acetaminophen | 12 | $188 | $16 |
2017: 10 drugs
| Imbruvica | 51 | $581,713 | $11,406 |
| Pomalyst | 15 | $227,944 | $15,196 |
| Hydroxyurea | 21 | $1,798 | $86 |
| Hydrocodone-Acetaminophen | 18 | $504 | $28 |
| Anastrozole | 17 | $491 | $29 |
| Dexamethasone | 22 | $475 | $22 |
| Acyclovir | 21 | $448 | $21 |
| Ondansetron | 26 | $423 | $16 |
| Allopurinol | 15 | $320 | $21 |
| Lorazepam | 13 | $116 | $9 |
2014: 2 drugs
| Nasonex | 11 | $1,845 | $168 |
| Tamoxifen Citrate | 20 | $352 | $18 |
2013: 2 drugs
| Anastrozole | 12 | $695 | $58 |
| Citalopram Hbr | 11 | $109 | $10 |
Money from drug and device companies
$1,000 in 2020
A payment is not proof that care is biased.
| CSL Behring | None | $1,000 | 1 payment
|
See the published payment
| CSL Behring | Travel · 2020-05-24 | None | $1,000 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2020 | Their institution | $240,807 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2020 | Their institution | $161,860 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2023 | Their institution | $119,516 |
| National Marrow Donor Program · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hem · 2022 | Their institution | $108,766 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2021 | Their institution | $62,657 |
| Kite Pharma, Inc. · A Phase 1/2 Open-Label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed Or Refractory Large B-Cell Lymphoma (Zuma-19) · 2020 | Their institution | $34,502 |
| Gilead Sciences, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2020 | Their institution | $31,302 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2021 | Their institution | $20,670 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2024 | Their institution | $19,443 |
| Kite Pharma, Inc. · A Phase 1/2 Open-Label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed Or Refractory Large B-Cell Lymphoma (Zuma-19) · 2021 | Their institution | $11,826 |
| Kite Pharma, Inc. · A Phase 1/2 Open-Label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed Or Refractory Large B-Cell Lymphoma (Zuma-19) · 2022 | Their institution | $8,967 |
Professional record
- NPI
- 1982754784
- Licence
- CA A67098California A67098: Current · expires 2026-12-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A670980
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-12
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.